Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant
Multiple myeloma (MM) with IgD M protein (IgD myeloma) is a rare subtype of MM that is considered an aggressive form of disease with worse prognosis. Due to its rarity, there are scarce data on the outcomes of IgD myeloma following autologous hematopoietic stem cell transplantation (autoHCT). This i...
Uloženo v:
| Vydáno v: | Transplantation and cellular therapy Ročník 31; číslo 2; s. S405 - S406 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Elsevier Inc
01.02.2025
|
| ISSN: | 2666-6367, 2666-6367 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Multiple myeloma (MM) with IgD M protein (IgD myeloma) is a rare subtype of MM that is considered an aggressive form of disease with worse prognosis. Due to its rarity, there are scarce data on the outcomes of IgD myeloma following autologous hematopoietic stem cell transplantation (autoHCT).
This is a single-center retrospective chart review study of IgD myeloma patients that received upfront autoHCT between 1988-2021. We conducted 1:3 propensity score matching (PSM) between patients with either IgD or IgG/IgA myeloma, according to the following variables: age, year of autoHCT (<2010, ≥2010), R2-ISS, HCT-CI (≤3, >3), induction treatment, conditioning regimen and use of maintenance treatment use (yes, no). Primary outcomes were progression-free survival (PFS) and overall survival (OS). High-risk cytogenetic abnormalities (HRCA) were defined as del17p, t(4;14), t(14;16) or 1q21 gain or amplification by fluorescence in situ hybridization (FISH).
Out of a total of 3041 patients with MM who received autoHCT during the study period at our center, we identified 39 patients with IgD myeloma. Of those, 29 (74%) were male, with the median age at autoHCT of 57 years; 36% (n=14) patients had HRCA (Table 1).
Prior to autoHCT, 59% of patients had achieved ≥VGPR, which increased to 78% and 82% at day 100 after autoHCT and at best post-transplant response evaluation, respectively (Figure 1). After a median follow up of 57 (range 6-202) months, the median PFS and OS for the entire cohort were 41 (95% CI 15-48) and 93 (95% CI 45-187) months, respectively (Figure 2). Three-year PFS and OS rates were 51% and 78%, respectively.
In multivariable analysis, achieving ≥CR at best post-transplant response was associated with better PFS (hazard ratio (HR) 0.4, p=0.049).
When comparing the IgD myeloma cohort to a matched cohort of IgG/IgA myeloma, we did not observe any difference in either PFS (HR 1.41, 95% CI 0.84-2.38; p=0.20) or OS (HR 1.01, 95% CI 0.54-1.90; p=0.98) between the two groups.
This is the largest study to date to evaluate outcomes of patients with IgD myeloma who received upfront autoHCT. Despite a high proportion of patients with HRCA, the median PFS was almost 3.5 years and the median OS was >7.5 years. Using PSM, we did not find any difference in survival outcomes between IgD myeloma and a matched cohort of IgG/IgA myeloma. |
|---|---|
| AbstractList | Multiple myeloma (MM) with IgD M protein (IgD myeloma) is a rare subtype of MM that is considered an aggressive form of disease with worse prognosis. Due to its rarity, there are scarce data on the outcomes of IgD myeloma following autologous hematopoietic stem cell transplantation (autoHCT).
This is a single-center retrospective chart review study of IgD myeloma patients that received upfront autoHCT between 1988-2021. We conducted 1:3 propensity score matching (PSM) between patients with either IgD or IgG/IgA myeloma, according to the following variables: age, year of autoHCT (<2010, ≥2010), R2-ISS, HCT-CI (≤3, >3), induction treatment, conditioning regimen and use of maintenance treatment use (yes, no). Primary outcomes were progression-free survival (PFS) and overall survival (OS). High-risk cytogenetic abnormalities (HRCA) were defined as del17p, t(4;14), t(14;16) or 1q21 gain or amplification by fluorescence in situ hybridization (FISH).
Out of a total of 3041 patients with MM who received autoHCT during the study period at our center, we identified 39 patients with IgD myeloma. Of those, 29 (74%) were male, with the median age at autoHCT of 57 years; 36% (n=14) patients had HRCA (Table 1).
Prior to autoHCT, 59% of patients had achieved ≥VGPR, which increased to 78% and 82% at day 100 after autoHCT and at best post-transplant response evaluation, respectively (Figure 1). After a median follow up of 57 (range 6-202) months, the median PFS and OS for the entire cohort were 41 (95% CI 15-48) and 93 (95% CI 45-187) months, respectively (Figure 2). Three-year PFS and OS rates were 51% and 78%, respectively.
In multivariable analysis, achieving ≥CR at best post-transplant response was associated with better PFS (hazard ratio (HR) 0.4, p=0.049).
When comparing the IgD myeloma cohort to a matched cohort of IgG/IgA myeloma, we did not observe any difference in either PFS (HR 1.41, 95% CI 0.84-2.38; p=0.20) or OS (HR 1.01, 95% CI 0.54-1.90; p=0.98) between the two groups.
This is the largest study to date to evaluate outcomes of patients with IgD myeloma who received upfront autoHCT. Despite a high proportion of patients with HRCA, the median PFS was almost 3.5 years and the median OS was >7.5 years. Using PSM, we did not find any difference in survival outcomes between IgD myeloma and a matched cohort of IgG/IgA myeloma. |
| Author | Nieto, Yago Bashir, Qaiser Saeed, Arsalan Orlowski, Robert Z. Shpall, Elizabeth J. Aljawai, Yosra M. Srour, Samer A. Ramdial, Jeremy L. Becnel, Melody R. Lee, Hans C. Qazilbash, Muzaffar H. Patel, Krina K. Haider, Asad A. Milton, Denai R. Champlin, Richard E. Pasvolsky, Oren Lin, Paul Saini, Neeraj Y. Thomas, Sheeba K. Kebriaei, Partow Tanner, Mark R. Tang, Guilin |
| Author_xml | – sequence: 1 givenname: Oren surname: Pasvolsky fullname: Pasvolsky, Oren organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 2 givenname: Denai R. surname: Milton fullname: Milton, Denai R. organization: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 3 givenname: Mark R. surname: Tanner fullname: Tanner, Mark R. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 4 givenname: Qaiser surname: Bashir fullname: Bashir, Qaiser organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 5 givenname: Samer A. surname: Srour fullname: Srour, Samer A. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 6 givenname: Neeraj Y. surname: Saini fullname: Saini, Neeraj Y. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 7 givenname: Paul surname: Lin fullname: Lin, Paul organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 8 givenname: Arsalan surname: Saeed fullname: Saeed, Arsalan organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 9 givenname: Asad A. surname: Haider fullname: Haider, Asad A. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 10 givenname: Jeremy L. surname: Ramdial fullname: Ramdial, Jeremy L. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 11 givenname: Yago surname: Nieto fullname: Nieto, Yago organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 12 givenname: Guilin surname: Tang fullname: Tang, Guilin organization: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 13 givenname: Yosra M. surname: Aljawai fullname: Aljawai, Yosra M. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 14 givenname: Partow surname: Kebriaei fullname: Kebriaei, Partow organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 15 givenname: Hans C. surname: Lee fullname: Lee, Hans C. organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 16 givenname: Krina K. surname: Patel fullname: Patel, Krina K. organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 17 givenname: Melody R. surname: Becnel fullname: Becnel, Melody R. organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 18 givenname: Sheeba K. surname: Thomas fullname: Thomas, Sheeba K. organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 19 givenname: Robert Z. surname: Orlowski fullname: Orlowski, Robert Z. organization: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 20 givenname: Elizabeth J. surname: Shpall fullname: Shpall, Elizabeth J. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 21 givenname: Richard E. surname: Champlin fullname: Champlin, Richard E. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX – sequence: 22 givenname: Muzaffar H. surname: Qazilbash fullname: Qazilbash, Muzaffar H. organization: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX |
| BookMark | eNqFkL1OwzAUhS1UJErpCzD5BRpsx3FSxFKVn1YqKhLtbDnOTXBx4ih2QX17UpUBMcB0z3C_o6PvEg0a1wBC15RElFBxs4t2QYeIEZZEhEaC8TM0ZEKIiYhFOviRL9DY-x0hhPGY0JgMUbXeB-1q8NiV-EUFA03w-NOEN7ys7vHz3gbTWsDPB7CuVnjbFNBVzjQVnu2Ds65ye48XUKvgWmcgGI1fA9R4DtbiTaca31rVhCt0XirrYfx9R2j7-LCZLyar9dNyPltNNOUpnxSljoEpIbI0ySmfTnmWijTPOC_SvISMM6pVxiiAynKtkjJL8zhNCICeFoRAPELs1Ks7530HpWw7U6vuICmRR1tyJ4-25NGWJFT2tnro7gRBv-zDQCe97kVoKEwH_W_hzN_47S9cW9MYrew7HP6DvwBZoYpr |
| ContentType | Journal Article |
| Copyright | 2025 |
| Copyright_xml | – notice: 2025 |
| DBID | AAYXX CITATION |
| DOI | 10.1016/j.jtct.2025.01.624 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2666-6367 |
| EndPage | S406 |
| ExternalDocumentID | 10_1016_j_jtct_2025_01_624 S2666636725006529 |
| GroupedDBID | .1- .FO 0R~ 1P~ 53G AAAJQ AAEDW AALRI AATTM AAXKI AAXUO AAYWO ABJNI ABUDA ACIEU ACLOT ACRLP ACVFH ADCNI ADVLN AEBSH AEHWI AEIPS AEUPX AFJKZ AFPUW AFRHN AFXIZ AIEXJ AIGII AIIUN AIKHN AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP AXJTR BNPGV CJTIS EBS EFJIC EFKBS EFLBG FDB FYGXN M41 ROL SPCBC SSH SSI SSU T5K Z5R AGCQF AGRNS AAYXX CITATION |
| ID | FETCH-LOGICAL-c1474-dfc3e2a66875b149948767b844d7bfe8421ca821eea8bca5f87b3750eec9d00e3 |
| ISSN | 2666-6367 |
| IngestDate | Sat Nov 29 07:47:27 EST 2025 Sat Aug 09 17:31:25 EDT 2025 Tue Oct 14 19:30:33 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1474-dfc3e2a66875b149948767b844d7bfe8421ca821eea8bca5f87b3750eec9d00e3 |
| ParticipantIDs | crossref_primary_10_1016_j_jtct_2025_01_624 elsevier_sciencedirect_doi_10_1016_j_jtct_2025_01_624 elsevier_clinicalkey_doi_10_1016_j_jtct_2025_01_624 |
| PublicationCentury | 2000 |
| PublicationDate | February 2025 2025-02-00 |
| PublicationDateYYYYMMDD | 2025-02-01 |
| PublicationDate_xml | – month: 02 year: 2025 text: February 2025 |
| PublicationDecade | 2020 |
| PublicationTitle | Transplantation and cellular therapy |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| SSID | ssj0002430130 |
| Score | 2.281512 |
| Snippet | Multiple myeloma (MM) with IgD M protein (IgD myeloma) is a rare subtype of MM that is considered an aggressive form of disease with worse prognosis. Due to... |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | S405 |
| Title | Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666636725006529 https://dx.doi.org/10.1016/j.jtct.2025.01.624 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2666-6367 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002430130 issn: 2666-6367 databaseCode: AIEXJ dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9swDBaydIddhg3bsHYP6LCb4cKWZUk-dm2HdkDabOuA3AzZpoMUqR20SdH9vv2xUZYVO0X26GEXI5EjwhG_UBTDjyTkg8hAxImK_Dxg2udMh75KRO5DVhZxIRkEhWqaTcizMzWZJOPB4KfjwtzOZVWpu7tk8V9VjWOobEOdfYC610JxAF-j0vGKasfrPyn-fLVEsbaW7NhWTW0pbKfTI2_kEghHP2BeX2mvaXw0rZvoyKppZmuSYk9MKdd6Uc8Mx9Gkgl15hybKZ2uhz3W1EdLvRi2cGq4cfrxJcV1u1i0Y6xu0iG3I9rzHRBvNXIPrI6j0zPu630UVXH8wwyzq3fhoOkE1N75o11PahTBY7LKenaVDJ0H4IrJ9OfZhy1hrqqOwB0nWs7vfeBD39nB8K7buDzZUcYnLk5tEWtbUbBWWxb1ZjPveJrlOXXRZcZepkZEaGWkQpijjEdlhEnE_JDsHp8eTz-tQH-OR-X_YtDl0X6qlb9lMw_sPs91F6rk9F8_I0_a8Qg8szp6TAVQvyNRhjNYldRijBmMUMUYdxmiLMdphjHYYoxsYowZj1GCMdmh6Sb5_Or44PPHbjh1-HnLJ_aLMI2BaCDwFZ3j2TvA4LGSmOC9kVoLiLMy1YiGAVlmu41LJLEKfFSBPiiCA6BUZVnUFrwnViUh4rHRUqJhrLdHWSGCZ1AoSAYXaJZ5bpHRhC7Okv9fNLoncOqaOcoybZIq4-OOseD2rdUito_mXeXsPerY35En3o3hLhsvrFbwjj_Pb5ezm-n0Lpl993rDH |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outcomes+of+Patients+with+IgD+Multiple+Myeloma+Undergoing+Autologous+Hematopoietic+Stem+Cell+Transplant&rft.jtitle=Transplantation+and+cellular+therapy&rft.au=Pasvolsky%2C+Oren&rft.au=Milton%2C+Denai+R.&rft.au=Tanner%2C+Mark+R.&rft.au=Bashir%2C+Qaiser&rft.date=2025-02-01&rft.issn=2666-6367&rft.eissn=2666-6367&rft.volume=31&rft.issue=2&rft.spage=S405&rft.epage=S406&rft_id=info:doi/10.1016%2Fj.jtct.2025.01.624&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jtct_2025_01_624 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2666-6367&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2666-6367&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2666-6367&client=summon |